Metastatik Olmayan İleri Evre Nazofaringeal Kanserde İndüksiyon veya Adjuvant Dosetaksel/Cisplatin Kemoterapisi
Abstract
Objective: Meta-analyses of randomized controlled trials was to determine the additional value of induction, concurrent, and/or adjuvant chemotherapy to radiation in the treatment of locally advanced nasopharyngeal carcinoma (NPC) with regard to the overall survival (OS) Material and Methods: A total of 28 patients with loacally advanced NPC were included for this trial. Docetaxel (75 mg/m2 on Day 1) and cisplatin (75 mg/m2 on Day 1) were administered every 21 days, after or before which concurrent chemoradiotherapy (CCRT) was administered. etkinliği ve toksite profili retrospektif olarak değerlendirildi The docetaxel/cisplatin regime and the toxicity profile were Bulgular: Objektif yanıt oranı (ORR) % 75 saptandı (13
References
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 200 Int J Cancer 2010;127(12):2893-917.
- Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10):1765-77. Al-Sarraf M, LeBlanc M, Giri PG.
- Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16(4):1310-7.
- Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study. Final
- Report (abstract 905). Proc Am Soc Clin Oncol 2001;20:227a.
- Akman F. Chemoradiotherapy in local advanced head and neck cancer. Turkiye Klinikleri J Med Oncol- Special Topics 2010;3(1):36-40.
- Keskin S, Bavbek S. Induction chemotherapy in lokally advanced head and neck cancer. Turkiye Kli- nikleri J Med Oncol-Special Topics 2010;3(1):32-5.
- Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27(2):242-9.
- Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemotherapy with radiotherapy alone in patients with carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008;71(5):1356-64. plus adjuvant locoregionally advanced nasopharyngeal
- Lee AW, Tung SY, Chua DT, et al. Randomized trial of chemotherapy vs radiotherapy alone for regionally plus advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010;102(15):1188-98. concurrent-adjuvant
- Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta- analysis of the published literature. J Clin Oncol 2004;22(22):4604-12.
- Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A Pooled Data Analysis of Two Phase III Trials J Clin Oncol 2005; 23(6):1118-24.
- Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal 2001;19(5):1350. J Clin Oncol
Metastatik Olmayan İleri Evre Nazofaringeal Kanserde İndüksiyon veya Adjuvant Dosetaksel/Cisplatin Kemoterapisi
Abstract
Giriş: Randomize kontrollü çalışmaların meta-analizlerinde
lokal ileri nazofaringeal karsinomada (NPC) indüksiyon,
konkürrent ve/veya adjuvant kemoterapinin radyoterapiye
ilave edilmesi overall survival (OS) ile ilişkili bulunmuştur.
Gereç ve Yöntem: Toplam 28 lokal ileri NPC li hasta çalış-
maya dahil edildi. Dosetaksel (75 mg/m2/ 1.gün ) ve
sisplatin (75 mg/m2/ 1.gün ) 21 günde bir konkürrent
kemoradyoterapi öncesinde veya sonrasında verildi.
Adjuvant veya indüksiyon dosetaksel/sisplatin rejiminin
etkinliği ve toksite profili retrospektif olarak değerlendirildi
Bulgular: Objektif yanıt oranı (ORR) % 75 saptandı (13
parsiyel yanıt, 8 tam yanıt). Stabil hastalık (SD) 7 (% 25)
hastada saptanırken progresif hastalık saptanmadı. İndüksiyon
kemoterapi alan hastalarda progresyonsuz sağ kalım
(PFS) 18.7 ay saptandı ve adjuvant kemoterapi alan grupta
ise anlamlılığa ulaşmadı. 3 yıllık PFS oranları sırasıyla % 20
ve % 66,9 saptandı (p:0.79). Median OS indüksiyon kemoterapi
grubunda 25.36 ay ve adjuvant alan grupta anlamlılığa
ulaşmadı. Sırasıyla 3 yıllık OS aranları % 26,7 ve % 72,2
saptandı (p:0.231).
Sonuç: Bizim çalışmamızda konkürrent kemoradyoterapiye
adjuvant kemoterapinin ilavesi geçmiş bilgilerle karşılaştırıldığında
ilave fayda getirmediği gösterildi. Bu hipotezin
araştırılması için daha ileri çalışmalar gereklidir
References
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 200 Int J Cancer 2010;127(12):2893-917.
- Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10):1765-77. Al-Sarraf M, LeBlanc M, Giri PG.
- Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16(4):1310-7.
- Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study. Final
- Report (abstract 905). Proc Am Soc Clin Oncol 2001;20:227a.
- Akman F. Chemoradiotherapy in local advanced head and neck cancer. Turkiye Klinikleri J Med Oncol- Special Topics 2010;3(1):36-40.
- Keskin S, Bavbek S. Induction chemotherapy in lokally advanced head and neck cancer. Turkiye Kli- nikleri J Med Oncol-Special Topics 2010;3(1):32-5.
- Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27(2):242-9.
- Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemotherapy with radiotherapy alone in patients with carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008;71(5):1356-64. plus adjuvant locoregionally advanced nasopharyngeal
- Lee AW, Tung SY, Chua DT, et al. Randomized trial of chemotherapy vs radiotherapy alone for regionally plus advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010;102(15):1188-98. concurrent-adjuvant
- Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta- analysis of the published literature. J Clin Oncol 2004;22(22):4604-12.
- Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A Pooled Data Analysis of Two Phase III Trials J Clin Oncol 2005; 23(6):1118-24.
- Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal 2001;19(5):1350. J Clin Oncol
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | August 1, 2014 |
| Published in Issue | Year 2014 Volume: 15 Issue: 2 |
Cite
